Identification of the molecular mechanisms of non-response to treatments, relapses and remission in autoimmune, inflammatory, and allergic conditions
Project factsheets
The Innovative Health Initiative builds on the successes of the Innovative Medicines Initiative (IMI), which launched over 180 projects. Many IMI projects are still ongoing and are monitored by the IHI Programme Office. This section features the factsheets of all IMI projects. Once IHI projects are up and running, we will also promote them here.
Displaying 102 projects/programmes
Antibiotic distribution and recovery in tissue
Autism Innovative Medicine Studies – 2 – Trials
Antimicrobial Resistance Accelerator
Amyloid imaging to prevent Alzheimer’s disease
Accelerating research & development for advanced therapies
Big Data for Better Outcomes
Behavioral and adherence model for improving quality, health outcomes and cost-effectiveness of healthcare
Biomarker enterprise to attack DKD
Big data @ heart
Central repository for digital pathology
Biomarkers in atopic dermatitis and psoriasis
conect4children - Collaborative network for European clinical trials for children
Cardiomyopathy in type 2 diabetes mellitus
Corona accelerated R&D in Europe
Combatting Bacterial Resistance in Europe - Carbapenem Resistance
Combatting bacterial resistance in Europe - molecules against Gram negative infections
Combatting Bacterial Resistance in Europe
Collaboration for prevention and treatment of MDR bacterial infections
Building an ecosystem for better monitoring and communicating of medication safety in pregnancy and breastfeeding: validated and regulatory endorsed workflows for fast, optimised evidence generation
COVID-19 infections - remote early detection
A minituarized disposable molecular diagnostics platform for combatting coronavirus infections
Rapid and secure AI imaging based diagnosis, stratification, follow-up, and preparedness for coronavirus pandemics
Development of Robust and Innovative Vaccine Effectiveness
EBiSC2 – A sustainable European bank for induced pluripotent stem cells
Ebola and other filoviral haemorrhagic fevers
Bringing a prophylactic Ebola vaccine to licensure
European Health Data and Evidence Network
European Platform for Neurodegenerative Diseases
European regimen accelerator for tuberculosis
European screening centre; unique library for attractive biology
Enhacing TRANslational SAFEty Assessment through Integrative Knowledge Management
EU patient-centric clinical trial platform
EUbOPEN: Enabling and unlocking biology in the OPEN
Framework for clinical trial participants data reutilization for a fully transparent and ethical ecosystem
FAIRplus
Novel Gram-negative antibiotic now
Gravitate–Health: Empowering and equipping Europeans with health information for active personal health management and adherence to treatment
H2O Health outcomes observatory
Healthcare alliance for resourceful medicines offensive against neoplasms in hematology
Healthcare alliance for resourceful medicines offensive against neoplasms in hematology – PLUS
Health initiatives in psoriasis and psoriatic arthritis consortium European states
Hypoglycaemia - REdefining SOLutions for better liVEs
Inhaled antibiotics in bronchiectasis and cystic fibrosis
Integrated control and sensing platform for biopharmaceutical cultivation process high-throughput development and production
Identifying digital endpoints to assess fatigue, sleep and activities in daily living in neurodegenerative disorders and immune-mediated inflammatory diseases
Investigating mechanisms and models predictive of accessibility of therapeutics (IM2PACT) into the brain
Improving the care of patients suffering from acute or chronic pain
Integrated immunoprofiling of large adaptive cancer patients cohorts
Specific imaging of immune cell dynamics using novel tracer strategies
Better control and treatment of immune-mediated diseases by exploring the universe of microenvironment imposed tissue signatures and their correlates in liquid biopsies
Development of Impentri, an intravenous imatinib formulation for COVID-19 acute respiratory distress syndrome (ARDS)
Immune safety avatar: nonclinical mimicking of the immune system effects of immunomodulatory therapies
Innovations to accelerate vaccine development and manufacture
Translational approaches to disease modifying therapy of type 1 diabetes: an innovative approach towards understanding and arresting type 1 diabetes.
Translational approaches to disease modifying therapy of type 1 diabetes - HARVESTing the fruits of INNODIA
ITCC pediatric preclinical POC platform
Evaluation of a production ready portable, point-of-need platform (instrument and reagents), direct from nasal swab test for the molecular diagnostic detection of COVID-19 infection
Liver Investigation: Testing Marker Utility in Steatohepatitis
Intermediate AMD: development of novel clinical endpoints for clinical trials in patients with a regulatory and patient access intention
Modern approaches for developing antivirals against SARS-CoV 2
Machine learning ledger orchestration for drug discovery
Connecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsement
New Drugs for Bad Bugs
New clinical endpoints in primary Sjögren’s syndrome: an interventional trial based on stratifying patients
Neurotoxicity de-risking in preclinical drug discovery
Optimal treatment for patients with solid tumours in Europe through artificial intelligence
PERtussIS COrrelates of Protection Europe
Building a reproducible single-cell experimental workflow to capture tumour drug persistence
Inflammation and AD: modulating microglia function - focussing on TREM2 and CD33
PharmaLedger
Prostate cancer diagnosis and treatment enhancement through the power of big data in Europe
Prioritisation and risk evaluation of medicines in the environment
Predicting the impact of monoclonal antibodies & vaccines on antimicrobial resistance
Psychiatric ratings using intermediate stratified markers 2
Preparing for RSV immunisation and surveillance in Europe
Proton versus photon therapy for esophageal cancer - a trimodality strategy
Remote assessment of disease and relapse – Alzheimer’s disease
Remote Assessment of Disease and Relapse in Central Nervous System Disorders
Robust automation and point of care identification of COVID
Real world handling of protein drugs - exploration, evaluation and education
Respiratory syncytial virus consortium in Europe
Research empowerment on solute carriers
Add medical genetic solutions to RESOLUTE (REsolution)
Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs
Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors
Rheuma Tolerance for Cure
Shortening the path to rare disease diagnosis by using newborn genetic screening and digital technologies
Establishing international standards in the analysis of patient reported outcomes and health-related quality of life data in cancer clinical trials
Stratification of obese phenotypes to optimize future obesity therapy
Saracatinib trial to prevent FOP
Accelerating development and improving access to CAR and TCR-engineered T cell therapy
Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease
Center of excellence – remote decentralised clinical trials
Boosting Ethionamide efficacy and lowering the dose with a small molecule transcriptional modulators, to overcoming MDR-TB infections and define a new place for Ethionamide in 1st-line TB treatments
Imaging biomarkers (IBs) for safer drugs: validation of translational imaging methods in drug safety assessment
Academia and industry united innovation and treatment for tuberculosis
Vaccine lot to vaccine lot comparison by consistency testing
The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use
Viral haemorrhagic fever: modern approaches for developing bedside rapid diagnostics
Vaccines and infectious diseases in the ageing population
Vaccine safety and immunogenicity signatures of human responses to VSV-ZEBOV
